Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Anixa Biosciences, Inc is a diagnostics & research business based in the US. Anixa Biosciences shares (ANIX) are listed on the NASDAQ and all prices are listed in US Dollars. Anixa Biosciences employs 3 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$3.97|
|52-week range||$1.70 - $8.09|
|50-day moving average||$4.03|
|200-day moving average||$4.48|
|Wall St. target price||$9.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.77|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-07-24)||N/A|
|1 month (2021-07-02)||4.75%|
|3 months (2021-05-04)||-13.51%|
|6 months (2021-01-31)||N/A|
|1 year (2020-07-31)||N/A|
|2 years (2019-07-31)||N/A|
|3 years (2018-07-31)||N/A|
|5 years (2016-07-31)||N/A|
|Gross profit TTM||$83,750|
|Return on assets TTM||-25.36%|
|Return on equity TTM||-45.31%|
|Market capitalisation||$143.5 million|
TTM: trailing 12 months
There are currently 790,021 Anixa Biosciences shares held short by investors – that's known as Anixa Biosciences's "short interest". This figure is 25.1% up from 631,373 last month.
There are a few different ways that this level of interest in shorting Anixa Biosciences shares can be evaluated.
Anixa Biosciences's "short interest ratio" (SIR) is the quantity of Anixa Biosciences shares currently shorted divided by the average quantity of Anixa Biosciences shares traded daily (recently around 112860.14285714). Anixa Biosciences's SIR currently stands at 7. In other words for every 100,000 Anixa Biosciences shares traded daily on the market, roughly 7000 shares are currently held short.
However Anixa Biosciences's short interest can also be evaluated against the total number of Anixa Biosciences shares, or, against the total number of tradable Anixa Biosciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Anixa Biosciences's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Anixa Biosciences shares in existence, roughly 30 shares are currently held short) or 0.0277% of the tradable shares (for every 100,000 tradable Anixa Biosciences shares, roughly 28 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Anixa Biosciences.
Find out more about how you can short Anixa Biosciences stock.
We're not expecting Anixa Biosciences to pay a dividend over the next 12 months.
Anixa Biosciences's shares were split on 17 October 2016.
Over the last 12 months, Anixa Biosciences's shares have ranged in value from as little as $1.7 up to $8.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Anixa Biosciences's is 1.4097. This would suggest that Anixa Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Anixa Biosciences, Inc. , a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell technology, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer; and the discovery and development of anti-viral drug candidates for the treatment of COVID-19 focused on inhibiting certain viral protein functions of the virus. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. It has a collaboration agreement with MolGenie GmbH to discover and develop anti-viral drug candidates against COVID-19. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc.
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
Everything we know about the RenovoRx IPO, plus information on how to buy in.
Everything we know about the Draganfly IPO, plus information on how to buy in.
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
Everything we know about the Marpai IPO, plus information on how to buy in.
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.